Title: Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)

Author list: 1 Rakesh Popat, 2 Sarah R Brown, 2 Louise Flanagan, 2 Andrew Hall, 2 Walter Gregory, Bhuvan Kishore, 4 Matthew Streetly, 5 Heather Oakervée, 1 Kwee Yong, 6 Gordon Cook, 7 Eric Low, and 5 Jamie Cavenagh, on behalf of the Myeloma UK Early Phase Clinical Trial Network

Affiliations:
1 NIHR/UCLH Clinical Research Facility, University College London Hospitals, London; 2 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds; 3 Heart of England NHS Foundation Trust, Birmingham; 4 Guys & St Thomas's Hospitals, London; 5 Barts Health NHS Trust, London; 6 Leeds Cancer Centre, Leeds; 7 Myeloma UK; 8

Full addresses:
1 NIHR/ UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, 4th Floor, 170 Tottenham Court Road, London W1T 7HA
2 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT
3 Heart of England NHS Foundation Trust, Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS
4 Guys and St Thomas's NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT
5 Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE
6 Leeds Cancer Centre, Beckett Street, Leeds, LS9 7TF
7 Myeloma UK, 22 Logie Mill, Beaverbank Business Park, Edinburgh EH7 4HG
Corresponding Author:

Dr Rakesh Popat

NIHR/ UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, 4th Floor, 170 Tottenham Court Road, London W1T 7HA

Email: rakesh.popat@ucl.ac.uk

Tel: 020 3447 8028 Fax: 020 3447 9911

Words: 983 (max 1000)
Panobinostat, a potent oral pan-deacetylase inhibitor is indicated for patients with relapsed multiple myeloma (MM) in combination with bortezomib and dexamethasone. This was based upon the subgroup analysis of the PANORAMA 1 phase 3 clinical trial demonstrating an improvement in progression free survival (PFS) of 12.5 vs 4.5 months (Richardson, et al 2016). MUK-six (ISRCTN59395590, NCT02145715) was a multi-centre phase I/II clinical trial for patients with relapsed MM (1-4 prior lines), designed to improve the efficacy, tolerability by adding low dose thalidomide and incorporating low intensity subcutaneous bortezomib followed by panobinostat maintenance. The epigenetic mechanism of action, role in aggressome disruption and evidence of immunomodulation (Govindaraj, et al 2014, Hideshima, et al 2005, Mitsiades, et al 2003) provided a hypothesis that continuing panobinostat monotherapy may prolong response. We previously reported primary and secondary endpoints for the trial interpreting that the regimen was efficacious and well tolerated (Popat, et al 2016). Here with extended follow-up, we report updated secondary endpoint of PFS, overall survival (OS) and feasibility of panobinostat maintenance.

Patients received bortezomib (V) 1.3mg/m^2 days 1, 8 with thalidomide (T) 100mg daily (50 mg if peripheral neuropathy) dexamethasone (D) 20mg days 1, 2, 8, 9 and panobinostat (P) days 1, 3, 5, 8, 10 and 12 of a 21 day cycle for 16 cycles followed by 1 year of panobinostat maintenance (current dosing level or maximum tolerated dose (MTD)) for patients completing 16 cycles of therapy only. The primary objectives were to determine the MTD of panobinostat and the overall response rate at the recommended dose within 16 cycles. The trial was funded by Myeloma UK, Novartis and approved by the UK national ethics committee and the Medicines and Healthcare Products Regulatory Agency (MHRA).

Following a median follow-up of 28 months, 46 patients received at least one dose of the recommended 20mg panobinostat dose and are reported for PFS overall; censoring patients coming off study for an autologous stem cell transplant (ASCT) at point of ASCT (see original paper for definitions and supplementary Figure for CONSORT diagram). The median overall PFS was 16.1 months (95%CI: 13.40, 21.55) and appeared similar for those with standard and adverse cytogenetic risk (standard (n=23) 16.10 months (95% CI: 13.40, 24.80), adverse (n=21) 17.90 months (95% CI: 9.40, Not calculable [>26.8]) 2, results not available, figure 1). 24 patients came off study to proceed to ASCT (median PFS 29.40 months (95% CI: 18.73, 37.65)) and 22 continued therapy (median PFS of 15.11 months (95% CI: 7.00, 20.47)). The median OS was not reached, for patients that did not come off to proceed to ASCT (n=22), the estimated 2 year OS was 71.4% (95% CI: 47.2%, 86.0%) (Figure 1).

15 of the 20 patients that completed 16 cycles of VTD-P went on to receive panobinostat maintenance (demographics in supplementary materials, table 1). Of the 5 that did not, 3 were eligible for ASCT and
2 had prior toxicity to panobinostat. Patients were predominantly at first relapse (11, 73.3%). 12 (80.0%) patients started maintenance at panobinostat 20mg and 3 at 15mg due to dose reductions during initial therapy. Clinic visits were six weekly for trial safety and response assessments (2 cycles of maintenance). Patients remained on maintenance for a median of 7.5 cycles (range 3-18). 5 completed the full 1 year, 9 stopped early due to disease progression and 1 withdrew consent for due to toxicity. 3 patients maintained their response during maintenance, 2 had disease progression at the end of the 1 year maintenance and 9 had disease progression on therapy with 1 patient beginning to lose the response (but not fulfilling criteria for disease progression) during maintenance before withdrawing after 4 cycles. No patients deepened their response on treatment (Figure 2). Median PFS for patients that received maintenance was 17.9 months (95% CI 13.4, 21.5). No serious adverse events were reported during maintenance. The commonest change in reported AEs from initial therapy (all grades) were diarrhoea (grade 1: 3/15, 20%; grade 3: 2/15, 13.3%), anorexia (grade 1: 4/15, 26.7%), infection (grade 1: 3/15, 20%; grade 2: 1/15, 6.7%). Overall treatment compliance was maintained with a median overall dose taken of 20mg (range 10-20mg). Four patients (26.7%) required at least 1 dose reduction for toxicity during maintenance, all requiring a reduction due to diarrhoea. Five patients (33.3%) required at least 1 dose omission of which 2 were due to nausea and diarrhoea.

In comparison, the phase 3 PANORAMA 1 trial which investigated VD-P (8 x 3 weekly cycles followed by 4 x 6 weekly cycles, with no maintenance) in patients with 1-3 prior lines of therapy (51% 1 prior line) reported a median PFS of 11.99 months (95% CI 10·33, 12·94, n=387) and OS of 40.3 months (95% CI, 35.0-44.8 months)[San-Miguel, et al 2014, San-Miguel, et al 2016]. Here we report an overall median PFS of 16.1 months, and 15.11 months for those that did not proceed to ASCT in a smaller phase I/II study (1-4 prior lines, 80% 1 prior line).

There is limited data to the efficacy of panobinostat monotherapy in MM. In a phase 2 trial of 38 patients, only 2 derived clinical benefit (1 PR, 1 MR). However both patients had long responses of 19 and 28 months (Wolf, et al 2012). A case report from a phase 1b trial of VD-P described 2 patients that gained long term benefit from ongoing panobinostat monotherapy (at least 65 months and 75 months) (Ocio, et al 2015). There are also ongoing trials investigating panobinostat post ASCT (Sengsayadeth, et al 2017). The MUK-six trial demonstrated that 1 year of panobinostat maintenance was feasible, with dose intensity maintained. The predominant AEs were gastrointestinal, mainly grade 1-2. Some maintained their response during maintenance; however 11 of the 15 patients developed disease progression on panobinostat. As a result, the clinical benefit of panobinostat
monotherapy maintenance appeared minimal. However the conclusions are limited due to a small selected group without comparative data.
Acknowledgements:

This trial was developed through the Myeloma UK Early Phase Clinical Trials Network, and funded by Myeloma UK and Novartis.

The authors acknowledge the patients who participated in this study, their families and carers as well as all staff, past and present, at the participating hospitals, Myeloma UK and the University of Leeds Clinical Trials Research Unit and the Independent Trial Steering Committee. This was a NIHR portfolio adopted trial and carried out and supported by the NIHR UCLH Clinical Research Facility and the Cancer Research UK Experimental Cancer Medicine Centre (ECMC). RP and KY are supported by the NIHR UCLH Biomedical Research Centre. JC, SB, EL, WG, KY designed the research; RP, JC, BK, MS, KY, GC performed the research and collected data; SB, AH performed statistical analyses; JC, RP, SB, AH, LF reviewed the trial report and interpreted data; LF performed trial and data management; RP, AH, SB wrote the manuscript; All authors reviewed the manuscript.


Figure Legends:

Figure 1: Progression free and overall survival of patients treated with VTD-P. A: PFS of all patients; B: PFS split for those that received ASCT and those that continued on therapy; C: PFS split by standard and adverse cytogenetic risk; D: OS split for those that received ASCT and those that continued on therapy.

Figure 2: Swim lane plot of each individual patient that received panobinostat maintenance following 16 cycles of VTD-P showing response at end of initial therapy and response over maintenance period.